In the present study, a model system for studying the role of nitric oxide (NO) in tumor growth and metastasis was reported. Incubation of Panc02 murine pancreatic adenocarcinoma cells in vitro with cytokines and interferon led to heterogeneous expression of NO synthase II (NOS II) protein. Clonal sublines expressing different levels of NOS II were then established using a limited dilution technique. After orthotopical implantation into the pancreas of syngeneic C57BL/6 mice, clones with a low level of NOS II expression produced tumors in pancreas, metastasized to the liver, and formed ascites, whereas those having a high level of NOS II expression did not. Liver-metastasis variants having low to high metastatic ability were also established using in vivo/in vitro passage. Compared with parental Panc02 cells exhibiting a high level of NOS II expression, these variants had a decreased level of NOS II expression. Furthermore, the heterogeneous Panc02 cells were injected intravenously into a large number of syngeneic mice. Variants that metastasized to the liver, lung, skin, peritoneum, ovary, and lymph nodes were established. All of the metastatic variants exhibited a lower level of NOS II expression than the parental Panc02 cell line did. However, the phenotypes of NOS II induction and metastatic ability were unstable. Multiple in vitro/in vivo selection led to stable low NOS II expression and high metastatic potential. Finally, to further confirm the role of NOS II expression derived from tumor cells in metastasis, poorly metastatic Panc02-H0 and highly metastatic Panc02-H7 cells were injected into the pancreas of syngeneic NOS II À/À mice, and groups of mice received i.p. injections of either phosphatebuffered saline or l-N 6 -(1-iminoethyl) lysine. Inhibition of NOS II activity in vivo significantly promoted distant liver metastasis. Collectively, these data show that NOS II expression is highly heterogeneous and dynamically regulated, which can directly influence tumor growth and metastasis.
Introduction
Metastasis is a complex process that involves multiple tumor-host interactions (Fidler and Balch, 1987; Xie and Fidler, 1998) . Recent studies have indicated that the nitric oxide (NO) synthase (NOS) plays an important role in the regulation of tumorigenicity and metastasis (Ambs et al., 1997; Fukumura and Jain, 1998; Lala and Orucevic, 1998; Wink et al., 1998; Xie and Fidler, 1998) . Three distinct isoforms of NOS have been identified, all of which catalyze the conversion of l-arginine to the free radical NO (Ignarro et al., 1987; Palmer et al., 1987; Nathan, 1992; Jaffrey and Snyder, 1995; Moncada, 1999) . The endothelial and neuronal NOS proteins are expressed constitutively and produce a trace amount of NO (low pm for seconds to minutes) that mediates physiologic functions such as neuronal transmission and vascular tone regulation (Palmer et al., 1987; Jaffrey and Snyder, 1995) . In sharp contrast, the NOS II protein is primarily expressed in activated macrophages (Palmer et al., 1987; Nathan, 1992; Moncada, 1999) . Once stimulated, NOS II generates large amounts of NO throughout the life of the active enzyme (mm for hours to days), and it has been shown to play an important role in host defense against pathogens and tumorigenic cells (Nathan, 1992; Xie and Fidler, 1998) .
As a potent cytotoxic molecule, NO participates in tumoricidal activity against many types of tumors via macrophages (Nathan, 1992; Xie and Fidler, 1998) . Tumor cells also express NOS II (Xie et al., 1993; Xie and Fidler, 1998) , the activation of which leads to NOmediated apoptosis of the cells (Xie et al., 1993 (Xie et al., , 1997a and regression of established metastases (Xie et al., 1995a) . In addition, enforced NOS II expression in tumor cells by NOS II plasmid transfection and retroviral infection suppresses tumorigenicity and metastasis (Xie et al., 1995a; Juang et al., 1998a, b) , and NOproducing cells cause autocytolysis and bystander cytolysis of tumor cells (Xie et al., 1997b) . Therefore, the elevated NOS II expression in tumor and tumor-infiltration host cells suppresses tumorigenicity and metastasis (Nathan, 1992) . Conversely, tumorrelated NOS II activity correlates with more advanced human tumors of the colon (Ambs et al., 1998) , breast (Thomsen et al., 1994) , and central nervous system (Cobb et al., 1995) . In fact, NOS II expression directly correlates with the metastatic potential of UV-2237 murine fibrosarcoma cells (Shi et al., 1999) . Transfection experiments have shown that a low level of NOS II expression promotes the growth of human colon cancer cells, although it is not clear whether the metastatic ability of the cells is affected (Jenkins et al., 1995; Ambs et al., 1998) . This discrepancy may reflect the difficulty of studying the role of NO in cancer metastasis because of the pleiotropic nature of NO action and complexity of cancer metastasis (Fidler and Balch, 1987; Nathan, 1992) . However, it is clear that the effects of NO production on tumor cells are output-dependent and cell-type-specific, and they are often dependent on the p53 functional status of the cells exposed to NO (Nathan, 1992; Ambs et al., 1997; Xie and Fidler, 1998; Wink et al., 1998) . It is also possible that during tumor progression, the NOS II expression machinery may be impaired in tumor cells and host infiltration cells such as macrophages (Nathan, 1992) ; the decreased level of NO production may be insufficient to produce significant tumoricidal activity. Instead, tumor cells appear to develop resistance to NO produced at a low level (Nathan, 1992; Lala and Chakraborty, 2001) . Although all the evidence suggests a close relation between NO production and tumor progression, the casual effect of NOS II expression on cancer metastasis remains unclear. Therefore, it is crucial to clearly understand the mechanisms of NOS II expression and NO action to target NOS II for cancer therapy. An important approach to this is the development of relevant in vitro and in vivo models.
In the present study, we established a syngeneic orthotopic model for Panc02 murine pancreatic adenocarcinoma metastasis and explored in great length the role of NO in cancer metastasis. We found that the parental Panc02 cell line was highly heterogeneous and its NOS II expression was dynamically regulated. The acquirement of metastatic phenotype required controlled NOS II expression.
Results

Heterogeneous expression of the NOS II gene in Panc02 cells
To determine the level of heterogeneous NOS II gene expression, Panc02 cells were incubated in vitro in the presence or absence of 10 U/ml IFN-g and 1 mg/ml LPS for 18 h. The NOS II expression in individual tumor cells was visualized via immunostaining using a specific antimouse NOS II antibody. Figure 1a shows that 20-40% of the Panc02 cells had a high level of NOS II protein expression, whereas 5-10% of the cells had little to no expression. Therefore, the induction of NOS II gene expression was highly heterogeneous. In this study, we used this cell line system to determine the dynamic relation between NOS II expression and metastatic ability.
Cloning of Panc02 subpopulations having different levels of NOS II expression
To determine the relation between NOS II expression and spontaneous metastatic ability, Panc02 cells were subjected to a limited dilution assay. To that end, more than 100 single-cell clones were collected. Initial screening for NOS II expression was performed by measuring nitrite accumulation in the culture supernatant after stimulating the cells for 18 h with 10 U/ml IFN-g and 1 mg/ml LPS. As shown in Figure 2 , NO production varied among the clonal cell lines. Most of the cell lines produced a moderate level of NO expression, whereas fewer cell lines produced either very little to no (p5 mm) or a very high level (X50 mm) of NO expression. Both four clones having high NO production and four having no noticeable NO production ( Figure 3a) were chosen for further study of NOS II gene expression using Northern blot analysis of NOS II mRNA. As shown in Figure 3b , CH1, CH2, CH3, and CH4 had a low constitutive level of NOS II gene expression, which was drastically induced 5-14-fold, whereas CL1, CL2, CL3, and CL4 had a low constitutive level of NOS II expression, which was not significantly induced by the same stimulation. We further compared the NOS II expression inducibility in CH4 and CL3 cells by different stimuli and their combinations. As shown in Figure 4 , higher NOS II induction by all of the treatments was seen in CH4 cells than in CL3 cells.
Metastatic potential of Panc02 clonal sublines
To determine their metastatic potential, the Panc02-H0 parental cell line and sublines listed above were injected into the tail of the pancreas of syngeneic C57BL/6 mice (2 Â 10 5 cells/mouse). The primary tumor formation in the pancreas, number of distant metastases in the liver, and amount of malignant ascites were determined 60 days after the tumor-cell injection. As shown in Table 1 , none of the clones having a high level of NOS II expression were tumorigenic or produced liver metastasis or ascites, whereas all of the clones having a low level of NOS II expression produced a primary tumor in the pancreas, metastasis to the liver, and ascites, although not in 100% of the animals. These data indicated that the level of NOS II expression was inversely correlated with the metastatic ability of the Panc02 sublines.
Stability of the NOS II expression phenotype
To determine the stability of the NOS II expression phenotype, we recloned the CH4 and CL3 cell lines. As we found initially, the majority of the subclones from CH4 produced NO at high levels ( Figure 5a , blue line), whereas the majority of the subclones from CL3 produced NO at low levels ( Figure 5b , blue line). However, after long-term in vitro culture (2-3 months), the majority of the subclones from CH4 intended to produce NO at lower levels actually produced it at moderate levels ( Figure 5a , red line). Similarly, the majority of the subclones from CL3 intended to produce NO at higher levels actually produced it at moderate levels ( Figure 5b, red line) . Furthermore, the cell lines' distribution patterns of NO production (red lines) approached the clonal distribution pattern of the parental Panc02-H0 cell line (dotted line). Therefore, the NOS II expression phenotype appeared to be unstable.
NOS II expression in cell lines established from metastases in different organs
Alternatively, we used a functional metastasis assay to determine the influence of NOS II expression on metastasis. The Panc02 parental cells were injected into the lateral tail vein of 100 mice (2 Â 10 5 cells/mouse). At 2 months after the tumor-cell injection, the mice were killed, and rare metastases in the ovary, peritoneal cavity, skin, lymph nodes, lung, and liver were The parental Panc02 cell line was cloned, and the 125 clonal sublines were incubated in medium alone or containing 10 U/ml IFN-g and 1 mg/ml LPS for 18 h. NO induction was determined by measuring nitrite accumulation in the culture supernatant. The clones were then divided into eight groups based on their ability to produce NO and expressed as the percentage of total clones. Very few of the subpopulations had a very low (o5 mm) or high (>50 mm) level of NO production were plated into two-well chamber slides. At 24 h after seeding, the cells were incubated in medium containing 10 U/ml IFN-g and 1 mg/ ml LPS for 18 h. The cells were then fixed for staining with a specific anti-NOS II antibody. The yellow arrows indicate cells positively stained for NOS II, while the red arrow indicates a NOS II-negative cell Nitric oxide and pancreatic cancer metastasis B Wang et al established as separate subcultures. The level of NOS II expression in cells forming these metastases was determined by measuring nitrite accumulation in the culture supernatant and Northern blot analysis of NOS II mRNA after stimulating the cells with 10 U/ml IFN-g and 1 mg/ml LPS for 18 h. As compared with Panc02 parental cells, which had a high level of NOS II expression, some of the cells forming the metastases had a low consititutive level of NOS II expression, which was not significantly induced by the same stimulation ( Figure 6 ). Therefore, only those cells having low NOS II inducibility metastasized, and/or there was a loss of NOS II inducibility in tumor cells that had had high NOS II inducibility during the process of metastasis.
However, we injected the tumor cells back into the mice after we obtained a sufficient number of them. There was not a significant number of metastases formed, as we expected (data not shown). To determine the cause of this, we established clonal subpopulations from the liver-metastasis cell line (Panc02-liver). We found that after long-term in vitro culture, the majority of the clones began to produce NO at moderate levels again, which was very much like the production of the parental Panc02 line (data not shown).
Establishment of a cell line that is highly metastatic to the liver The metastatic cells listed above have a low level of NOS II expression. Therefore, we asked whether there is a further loss of or stable NOS II expression in further tumor progression. Parental Panc02-H0 murine Figure 3 NOS II expression in the parental Panc02 (H0) cell line and its clonal sublines, CH1, CH2, CH3, CH4, CL1, CL2, CL3, and CL4. The cell lines were incubated in medium alone or containing 10 U/ml IFN-g and 1 mg/ml LPS for 18 h. NOS II mRNA was determined using Northern blot analysis (a), and NO production was determined by measuring nitrite accumulation in the culture supernatant (b) Figure 4 Induction of NOS II expression in Panc02-CH4 and -CL3 cells. The cells were incubated in medium alone or containing 10 U/ml IFN-g, 1 ng/ml IL-1a, 1 ng/ml TNF-a, 1 mg/ml LPS, or various combinations thereof for 18 h. NOS II mRNA was determined using Northern blot analysis, and NO production was determined by measuring nitrite accumulation in the culture supernatant. Synergistic NOS II induction required IFN-g in both CH4 and CL3 cells To characterize the behavior of the cell lines growing in vivo, parental H0, H1, H2, H3, H4, H5, H6, and H7 cells were injected into the pancreas of C57BL/6 mice (groups of 10, 2 Â 10 5 cells/mouse). All of the mice were killed 30 days after the tumor-cell injection or when they became moribund. As shown in Table 2 , with the increase in vivo/in vitro passage, the tumorigenic and metastatic potential increased. Also, Panc02-H5, -H6, and -H7 cells produced a tumor, metastasis, and ascites at an incidence of 100%.
NOS II expression in Panc02 sublines metastatic to the liver
To determine the level of NOS II expression in cell lines having different ability to form liver metastasis, the parental Panc02 cell line and its sublines H1, H3, H5, and H7 were incubated with 10 U/ml IFN-g and 1 mg/ml LPS for 18 h. The expression level was determined using Figure 5 Stability of the NOS II induction phenotype. Panc02-CL3 and -CH4 cells and their respective long-term cultures CL-3-LP and CH4-LP were subcloned, and the subclonal sublines (154 for CL3, 123 for CL3-LP, 92 for CH4, and 113 for CH4-LP) were incubated in medium alone or containing 10 U/ml IFN-g and 1 mg/ ml LPS for 18 h. NO induction was determined by measuring nitrite accumulation in the culture supernatant. The subclones of CL3 and CL3-LP (a) and CH4 and CH4-LP (b) were then divided into eight groups based on their ability to produce NO and expressed as a percentage of the total clones. The majority of the subpopulations in CH4 had a very high (X50 mm) level of NO expression, whereas the majority of the subpopulations in CL3 had a very low (p5 mm) level of NO expression. The arrows indicate the drift directions of distribution of NO-producing clones (CL3-LP and CH4-LP) after long-term culture in vitro, while the dotted line represents the distribution pattern of parental Panc02 subpopulations Figure 6 NOS II expression in different organ-metastasis sublines. The parental Panc02 cell line and its metastatic sublines from different organs were incubated in medium alone or containing 10 U/ml IFN-g and 1 mg/ml LPS for 18 h. NOS II mRNA was determined using Northern blot analysis (a), and NO production was determined by measuring nitrite accumulation in the culture supernatant (b). All of the metastatic cells had a very low level of NOS II expression Nitric oxide and pancreatic cancer metastasis B Wang et al Northern blot analysis of NOS II mRNA and by measuring nitrite accumulation in the culture supernatant. As shown in Figure 7 , parental H0 cells had a high level of NOS II expression and produced NO at a high level after stimulation, whereas none of the sublines metastatic to the liver produced NO at a noticeable level and had only a low constitutive level of NOS II mRNA expression. However, there were no detectable levels of NOS II protein by Western blot analysis (Figure 7c ), although marginal levels of NOS II activity were evident in the l-citrulline assay (Figure 7d) ). Interestingly, there was no further loss of NOS II expression with an increase in metastatic ability. We again established clonal subpopulations from both the Panc02-H2 and -H7 cell lines metastatic to the liver. We found that after long-term in vitro culture, the majority of the clones from Panc02-H2 began to produce NO at moderate levels again, which was very much like the NO production of clones from the parental Panc02, Panc02-liver, and Panc02-H1 lines (data not shown), whereas the majority of the clones from Panc02-H7 maintained low NO production. These data suggest that further progression required stabilization of NOS II expression at a low level rather than further loss of it. 10/10 1.2 (0.7-1.7)** 10/10 100 (32-100)** 10/10 1.5 (1.2-5.2)** a Number of mice with tumors in the injection sites, metastases, or ascites/total number of mice *Po0.05 and **Po0.01 as compared with the H0 cells Tumor cells (2 Â 10 5 cells/mouse for each cell line) were injected into the pancreas of groups of 10 C57BL/6J mice. The animals were killed 20 days after tumor implantation or when they became moribund. The weight of pancreas tumors, number of liver metastases, and amount of ascites were determined Figure 7 NOS II expression in progressively increased liver-metastasis sublines of the parental Panc02 cell line. Panc02 and its livermetastasis sublines, H1, H3, H5, and H7, were incubated in medium alone or containing 10 U/ml IFN-g and 1 mg/ml LPS for 18 h. NOS II mRNA was determined using Northern blot analysis (a), and NO production was determined by measuring nitrite accumulation in the culture supernatant (b). NOS II protein expression was determined by Western blot analysis (c) and enzymatic assay (d). NOS II KX-dwl (dwl) cells were used as negative controls. Dotted lines represent the detection limits of the assays C57BL/6J mice. Specifically, primary pancreas tumors, ascites, and liver metastases were collected and processed for NOS II mRNA using Northern blot analysis. Also, ascites and serum were collected, and the nitrite/ nitrate concentration was determined using serum collected from mice that did not receive an injection of tumor cells as a control. As shown in Figure 8a , NOS II mRNA was detected in the tumor but not in normal pancreatic tissue and a significant lower level NOS II was also detected in liver metastases. Consistent with the NOS II mRNA expression, a high level of nitrite/nitrate was detected in the ascites and serum of mice carrying H7 tumors and totally inhibited by l-N 6 -(l-iminoethyl) lysine (l-NIL) (Figure 8b ), whereas the level was low to undetectable in the serum of normal mice. Therefore, progressively growing Panc02-H7 cells still expressed NOS II and produced NO in vivo, but the liver metastases exhibited much lower NOS II expression.
Inhibition of NOS II expression in vivo
To determine the effect of inhibition of NOS II expression on the growth and metastasis of Panc02-H7 cells having a low level of NOS II expression and Panc02-H0 cells having a high level of NOS II expression, these cells were injected into the pancreas of NOS II À/À C57BL/6J mice, and an i.p. injection of l-NIL (2.5 mg/mouse) was given to them twice daily throughout the experiment. Tumor growth and metastasis were determined 20 (for Panc02-H7 cells) or 45 (for Panc02-H0 cells) days after the tumor-cell injection. l-NIL treatment totally inhibited NO production in vivo (Figure 8b ) and slightly inhibited tumor growth but significantly enhanced liver metastasis (Table 3) . We obtained a similar result from using aminoguandine, another relatively selective NOS II inhibitor (data not shown). These data suggest that both low and high levels of NOS II expression differentially influenced tumor growth and metastasis.
Discussion
Metastasis is a complex process involving multiple tumor-host interactions (Fidler and Balch, 1987; Xie and Fidler, 1998) , and recent studies have indicated that the NOS II gene plays an important role in the regulation of tumorigenicity and metastasis (Ambs et al., 1997; Lala and Orucevic, 1998; Wink et al., 1998; Xie and Fidler, 1998) . We have further suggested that manipulation of NOS II expression and NO production may prove to be a novel approach to controlling tumor growth and metastasis (Xie and Fidler, 1998) . However, during tumor progression, the NOS II expression machinery may be impaired in tumor cells (Ambs et al., 1997; Xie and Fidler, 1998) as well as host-infiltration cells such as macrophages (Dinapoli et al., 1996) . In addition, tumor cells appear to develop resistance to NO at lower levels (Ambs et al., 1997; Xie and Fidler, 1998; Lala and Chakraborty, 2001 ). Therefore, to design effective therapy logically, it is crucial to understand clearly both the mechanisms of NOS II expression and NO action, most notably those in tumorinfiltration macrophages, and their causal antitumor activity. An important approach to this is the development of relevant in vitro and in vivo models (Wang et al., 2001a; Xie et al., 2001) . In the present study, we established a syngeneic orthotopic model for Panc02 murine pancreatic adenocarcinoma metastasis and explored in great length the role of NO in cancer metastasis and its potential application in the designing of a novel therapeutic strategy. We found that the parental Panc02 cell line was highly heterogeneous and that the metastatic and nonmetastatic subpopulations isolated from their parental cell line differed in their level of NOS II expression both in vitro and in vivo, that is, metastatic cells appeared to have lower NOS II inducibility than nonmetastatic cells. Additionally, blocking the NOS II activity promoted the metastasis of tumor cells having a low level of NOS II expression to the liver. Therefore, we provided an excellent model for studying the biology of and therapy for pancreatic cancer in general and further investigation of the role and regulation of NO production in the growth and metastasis of pancreatic cancer specifically. It has been well known that a tumor is biologically heterogeneous regarding such characteristics as radiation sensitivity, drug resistance, angiogenic ability, and metastasis (Fidler and Balch, 1987) . In this study, we showed that Panc02 tumors are highly heterogeneous regarding NOS II expression. Three distinct approaches were used to define the relation between NOS II induction and metastasis formation. First, we isolated clonal cell lines that differed in their NOS II inducibility. We found that none of the clones having a high level of NOS II expression were tumorigenic or produced liver metastasis or ascites, whereas all of the clones having a low level of NOS II expression produced a primary tumor in the pancreas, metastasis to the liver, or ascites, although not in 100% of the animals. Consistent with our previous report (Radomski et al., 1991; Dong et al., 1994; Moochhala et al., 1996) , the level of NOS II expression was inversely correlated with the metastatic ability of Panc02 sublines, suggesting that a high level of NOS II expression suppresses tumor growth and metastasis.
Alternatively, a functional metastasis assay was used to determine the relation between NOS II expression and metastatic potential. We used the host as selection pressure to produce cell lines from established metastases and determine their level of NOS II expression in comparison with that of their parental lines (Xie et al., 2001) . Specifically, Panc02 parental cells were injected into the lateral tail vein of mice. Metastases in the ovary, peritoneal cavity, skin, lymph nodes, lung, and liver were established as separate subcultures, and the level of NOS II expression in the metastatic cells was determined. Compared with parental Panc02 cells, which had a high level of NOS II expression, the cells forming the metastases had a low constitutive level of NOS II expression, which was not significantly induced by the stimulation. Therefore, it is possible that the cells having low NOS II inducibility were able to survive and then metastasize, suggesting that selection may have occurred (Ambs et al., 1997; Xie and Fidler, 1998) . It is also possible that there was a loss of NOS II inducibility in tumor cells that had had high NOS II inducibility in the process of metastasis, suggesting that adaptation may have occurred (Ambs et al., 1997; Xie and Fidler, 1998 ). Nevertheless, a high level of NOS II expression prevents tumor growth and metastasis.
However, after long-term culture and then injection back into the mice, clonal cell lines differing in their level of NOS II expression did not exhibit a difference in their incidence of metastasis formation. Moreover, longterm-cultured tumor cells established from a metastasis did not show increased metastatic incidence. Therefore, the metastatic phenotype was not stable. These findings may be explained by several factors. We first speculated that the NOS II expression phenotype is simply not stable, which was based on several experiments. For example, we established clonal subpopulations from the liver-metastasis cell line Panc02-liver and found that after long-term culture in vitro, the majority of the clones began to produce NO at moderate levels again, which was very much like the production of the parental Panc02 line. Similarly, we also recloned the CH4 and CL3 cell lines. Initially, we found that the majority of the subclones from CH4 and CL3 produced NO at high and low levels, respectively. However, after long-term culture in vitro, the majority of the subclones from CH4 intended to produce NO at lower levels actually produced it at moderate levels. Likewise, the majority of the subclones from CL3 intended to produce NO at higher levels actually produced it at moderate levels. Also, the distribution patterns of the clones' NO production approached that of the parental Panc02-H0 cell line. Consistent with the shift in NOS II expression, the metastatic potential of cell clones shifted to the opposite direction, that is, original clones that had a high level of NOS II expression and were lowly metastatic actually had a moderate to low NOS II expression level and became more metastatic, whereas the original clones that had a low level of NOS II Median ( expression and were metastatic actually had a low to moderate NOS II expression level and became less metastatic. Therefore, both the NOS II expression and metastatic phenotype appeared to be unstable, and their relation was quite dynamic. A similar observation was made using human pancreatic cancer cells (data not shown). The genetic instability and phenotypic diversification may be responsible for the heterogeneity of the original tumor and for the instability of NOS II expression in its clonal suhlines. A detailed comparative analysis of human and murine NOS II promoter may help elucidate the molecular mechanisms governing the expression and regulation of NOS II gene. Whether NOS II gene induction also is influenced by cell cycle stage is currently under investigation. Therefore, NOS II expression may be regulated by both genetic and epigenetic mechanisms.
Furthermore, we asked whether there is a further loss of or stable NOS II expression in the subsequent tumor progression. Using the procedure described by Fidler, we established a series of liver-metastasis variants having gradually increasing metastatic potential (Wang et al., 2001a) . As compared with parental Panc02-H0 cells that had a high level of NOS II expression and produced NO at a high level after stimulation, none of the liver-metastasis sublines produced NO at a noticeable level, and they had only a low constitutive level of NOS II mRNA expression. Interestingly, there was not a further loss of NOS II expression with the increase in metastatic ability. In addition, we again established clonal subpopulations from both the Panc02-H2 and -H7 cell lines. We found that after long-term culture in vitro and similar to the clones from the parental Panc02, Panc02-liver, and Panc02-H1 lines, the majority of the clones from Panc02-H2 began to produce NO at a moderate level again, whereas the majority of the clones from Panc02-H7 maintained low NO production. These data suggest that the NOS II expression and metastatic phenotypes were not stable in early-passage cells (H1 or H2) but stabilized in late-passage cells (H7). Therefore, further progression did not require further loss rather than stabilization of NOS II expression at a low level.
The data presented above may indicate that the H7 cells maintained high metastatic potential through controlling NOS II expression at a low level. One reason may be that uncontrolled NOS II expression would lead to the production of NO at a cytotoxic level and suppress tumor growth and metastasis. This notion is supported by several recent studies indicating that controlled expression of NOS II is apparent during tumor progression . For example, human colon carcinoma cells isolated from metastases exhibit lower NOS II activity than do tumor cells isolated from the primary neoplasm (Radomski et al., 1991) . Also, compared with normal colon epithelium, colonic adenomas exhibit reduced NOS II expression, whereas colorectal adenocarcinomas lose NOS II expression (Moochhala et al., 1996) . This observation was confirmed by several other studies of various types of tumors, including breast cancer (Thomsen et al., 1994) . Although highly descriptive, these studies strongly suggest that an apparent loss of NOS II expression is associated with tumor progression. In fact, NOS II expression inversely correlates with the ability of tumor cells to survive and produce metastases as demonstrated using the well-characterized K-1735 melanoma system (Moochhala et al., 1996) , which clearly indicated that the loss of NOS II expression in tumor cells correlates with a gain in metastatic potential. This has been tested further in our recent studies, which have shown that NOS II expression as well as NO production and its antitumor activity can be enhanced by the localized production of interferon-b, a potent NOS II inducer (Wang et al., 2001b) , and that disruption of the NOS II gene impaired this antitumor activity Shi et al., 2000) . In contrast, NOS II expression was significantly decreased with accelerated tumor growth in mice having disruption of the IFN-g gene (Wang et al., 2001c) , which is essential for synergistic NOS II induction (Nathan, 1992; Xie and Fidler, 1998) . Therefore, elevation of the availability of NOS-IIinducing cytokines can effectively increase NOS II expression and NO-mediated tumor suppression.
Finally, we determined whether a low level of NOS II expression is necessary for further tumor progression. We first determined whether NOS II was expressed in Panc02-H7 cells growing in the pancreas of NOS II À/À C57BL/6J mice to exclude the host NOS II expression. As shown in multiple approaches, the progressively growing Panc02-H7 cells still expressed NOS II and produced NO in vivo. Then, we determined the effect of inhibition of NOS II expression on the growth and metastasis of Panc02-H7 cells using l-NIL. Paradoxically, l-NIL treatment totally inhibited NO production in vivo and slightly inhibited tumor growth but significantly enhanced liver metastasis. These data suggest that the low level of NOS II expression differentially influenced tumor growth and metastasis. Our recent studies have shown that disruption of the host NOS II gene differentially affects tumor growth and metastasis (Shi et al., 2000; Wang et al., 2001d) , which apparently correlates with intrinsic sensitivity to NO-mediated cytotoxicity (Shi et al., 2000) . Therefore, during tumor progression, tumor cells may strategically control NOS II expression and develop NO resistance. The mechanisms by which tumor cells control NOS II expression and resist NO remain to be determined. We are currently investigating whether increased methylation activity is responsible for decreased NOS II expression in metastatic cells. Our findings may have significant implication in human pancreatic cancer. Recent study has shown that human pancreatic cancer expresses NOS II Nussler et al., 1998; Kong et al., 2001) . The expression levels inversely correlated with patient prognosis (Kong et al., 2001) . Specifically, increased NOS II expression correlated with increased apoptosis of tumor cells (Kong et al., 2001) . This is consistent with another report showing that appropriate stimulation of various human pancreatic cancer cells leads to the production of endogenous NO and cell death by apoptosis . Additionally. NO may influence metastasis via many other mechanisms (Xie and Huang, 2003) , including regulation of MMP expression and activity and modulation of platelet function (Jurasz et al., 2001; Martinez et al., 2001) .
In summary, we found that during tumor progression, NOS II expression may be dynamically (temporally and spatially) regulated in tumor cells and differentially influences tumor growth and metastasis. In the early stages of progression, both NOS II expression and metastatic phenotypes appear to be unstable, whereas in the more advanced stages, NOS II expression is well controlled at a low level to minimize its negative influence on tumor growth and metastasis. Further understanding of NOS II expression may shed more light on tumor progression and help in designing novel therapy for metastatic cancer.
Materials and methods
Reagents
RPMI-1640 medium, fetal bovine serum, and phenol-extracted Salmonella LPS were purchased from Sigma Chemical Co. (St Louis, MO, USA). Mouse recombinant IFN-g (sp. act., 1 Â 10 7 U/mg protein), TNF-a, and IL-1a were purchased from Genzyme (Cambridge, MA, USA). All reagents used in tissue cultures were free of endotoxins as determined using the Limulus Amebocyte Lysate assay (sensitivity limit, 0.125 ng/ ml; Associates of Cape Cod, Woods Hole, MA, USA).
Animals
Female NOS II wild-type (NOS IT +/+ ) and knockout (NOS II À/À ) C57BL6/J mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed in laminar flow cabinets under specific pathogen-free conditions and used when they were 8 weeks old. The animals were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care in accordance with the current regulations and standards of the US Department of Agriculture, Department of Health and Human Services, and National Institutes of Health.
Cell lines and culture conditions
The Panc02 murine ductal adenocarcinoma cell line was gifted by Dr James Nelson (The University of Texas M D Anderson Cancer Center, Houston, TX, USA). All cell lines, including Panc02 and its variants, were maintained in plastic flasks as adherent monolayers in RPMI-1640 medium supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, l-glutamine, and vitamin solution (Flow Laboratories, Rockville, MD, USA). Panc02 was originally established by Corbett et al. (1984) by implanting cottonthread-carrying 3-methylcholanthrene into the pancreas of C57BL/6 mice followed by serial s.c. transplantation.
Preparation of tumor cells for culture from metastases
Individual metastases were obtained immediately after surgery and processed as follows. Tumor tissue was rinsed several times in cold (41C) culture medium and then cut into fine fragments using a sterile scalpel. The fragments were then subjected to sequential enzymatic digestion for 30 min at 371C in a medium containing collagenase type I and DNase. After enzymatic dissociation, the cells were maintained at 41C. Finally, the cell suspension was filtered through a four-layer sterile gauze, washed three times in serum-free medium, and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum.
Cell cloning
The cell number was adjusted to 2.5 cells/ml in medium containing 20% fetal bovine serum. Tumor cells (0.5 cells/ 0.2 ml of medium) were seeded into 96-well plates (10 plates are normally needed to obtain about 100 single-cell clones). After the cells settled (which usually takes 4-8 h), the number of cells in each well was determined. Wells containing single cells were marked and further confirmed 3 days after initial seeding. Clonal cells were harvested when they covered about 30% of the well surface and then transferred to either six-well plates or T-75 flasks depending on their growth ability. The clones and parent tumor culture were frozen and stored until enough clones were ready for the in vitro and in vivo comparative experiments.
Tumor growth and metastasis
For all in vivo experiments, tumor cells in the exponential growth phase were harvested after brief exposure to a 0.25% trypsin/0.02% EDTA solution (w/v). The flask was tapped sharply to dislodge the cells, MEM was added, and the cell suspension was pipetted to obtain single-cell suspensions. Next, the cells were washed, resuspended in Ca 2+ -and Mg 2+ -free HBSS, and diluted to the desired cell number/inoculum. Cell viability was determined using trypan blue exclusion; only single-cell suspensions of >95% viability were used to determine tumorigenic and metastatic potential using orthotopic xenograft models. In brief, nude mice were anesthetized using methoxyflurane and placed in the supine position. Then, an upper midline abdominal incision was made, and the pancreas was exteriorized. Tumor cells (2 Â 10 5 in 0.05 ml of HBSS) were then injected into the tail of the pancreas. The animals were killed 30 days after the tumor-cell inoculation, when they became moribund, or as indicated. Afterwards, ascites was collected, and tumors in the pancreas were harvested and weighed. Also, the animals' livers were fixed in Bouin's solution for 24 h to differentiate the neoplastic lesions from the organ parenchyma, and liver metastases were counted (double-blinded) with the aid of a dissecting microscope and routinely confirmed by histology as described previously (Xie et al., 1995a) .
Use of l-NIL in vivo l-NIL is a selective NOS II inhibitor (Alexis Biochemicals, San Diego, USA), which was shown in several recent studies (Moore et al.,. 1994 ). Administration of l-NIL can effectively inhibit NO production in a mouse model. In the present study, parallel groups of mice received an i.p. injection of l-NIL (2.5 mg/mouse) twice daily. l-NIL administration started on the day of the tumor-cell injection or as indicated and continued throughout the experiment.
Northern blot analysis
To measure NOS II mRNA expression, Panc02 and its variants were cultured under in vitro conditions. Cellular mRNA was extracted using the FastTrack mRNA isolation kit (Invitrogen Co., San Diego, CA, USA). The mRNA (2 mg) was separated electrophoretically on a 1.0% denaturing formaldehyde agarose gel, transferred to a GeneScreen nylon membrane (DuPont Co., Boston, MA, USA) in 20 Â standard saline citrate, and UV-crosslinked using the UV-Stratalinker 1800 (Stratagene, La Jolla, CA, USA). In addition, the NOS II cDNA probe was labeled with [ 32 P]-deoxycytidine triphosphate using a random labeling kit (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA). Equal loading of mRNA samples was monitored by hybridizing the same membrane filter with a human b-actin cDNA probe (Shi et al., 2000) .
Western blot analysis of NOS II expression
Cell lysalcs were prepared from cell culture. Protein concentration was measured by the Bradford method (Bio-Rad). A standard Western blot was performed using a rabbit anti-mouse NOS II polyclonal antibody (Transduction Laboratories, Lexington, KY, USA) and a second antibody [anti-rabbit Ig, horseradish peroxidase-linked from a donkey, Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA]. Equal protein sample loading was monitored by hybridizing the same membrane filter with an anti-b-actin antibody (Wang et al., 2000b) . The probe proteins were detected using the Amersham enhanced chemiluminescence system according to the manufacturer's instructions.
NOS II enzymatic activity assay
The NOS II activity was assayed by the conversion of | 14 C|arginine to | 14 C|citrulline using a commercial NOS assay kit (Sigma Chemical Co.). Briefly, the cells were detached with a cell scraper and suspended in a 1 Â homogenization buffer containing 25 mm Tris-HCl, 1 mm EDTA, and l mm EGTA. After homogenizing the cell by using a tissue grinder, pipet the cell homogenate into microcentrifuge tubes, and spin the tubes in a microcentrifuge at full speed for 5 min at 41C. The supernatant was collected in a tube and kept on ice until used. For NOS II activity assay, 25 ml of cell homogenate corresponding to approximately 25 mg of protein were incubated at 371C for 1 h in a reaction mixture containing 50 m HEPES (pH 7.4 at 371C), 1 mm EDTA, 0.5 Mmnadph, 5 mm FAD, 5 mm FMN, 10 mg/ml calmodulin and 50 nm | 14 C| l-arginine (Amersham Pharmacia Biotech Inc.). Calcium chelators EDTA and EGTA were used in order to measure the NOS enzymatic activity of calciumindependent NOS II. The reaction was stopped by adding 2 ml of ice-cold 20 mmol/l HEPES (pH 5.5) containing 5 mmol/l EDTA. The sample was applied onto a Dowex AG 50W-X8 column that had been preequilibrated with 20 mmol/l HEPES (pH 5.5). The radioactivity of eluate, which contained | 2 H|l-citrulline, was quantified by liquid scintillation counter and expressed as counts per minute (c.p.m.) per mg of protein per minute.
Measurement of NO production in vitro and in vivo
Nitrate in serum was first converted to nitrite via incubation at 371C for 15 min with 0.1 U/ml nitrate reductase (Boehringer Mannheim Biochemicals), 0.2 mm NADPH, and 5.0 mm FAD. The reaction was stopped by adding 10 U/ml lactic dehydrogenase (Sigma Chemical Co.) and 10 mm sodium pyruvate. The total nitrite concentration in the culture supernatants was then determined using a microplate assay. Briefly, 50-ml samples were allowed to react with an equal volume of Greiss reagent (1.0% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, and 2.5% H 3 PO 4 ) at room temperature for 10 min; the absorbance at 540 nm was monitored using a microplate reader. The nitrite concentrations were determined using sodium nitrite as a standard (Shi et al., 2000) .
Immunocytochemistry
Tumor cells growing on chamber slides were fixed in cold acetone. Endogenous peroxidase was blocked using 3% hydrogen peroxide in phosphate-buffered saline (PBS) for 12 min. The tumor samples were incubated for 20 min at room temperature with a protein-blocking solution consisting of PBS (pH 7.5) containing 5% normal horse serum and 1% normal goat serum and then incubated at 41C in a 1 : 50 dilution of rabbit polyclonal anti-NOS II antibody (Transduction Laboratories). The samples were then rinsed and incubated for 1 h at room temperature with peroxidaseconjugated anti-rabbit IgG and then rinsed with PBS and incubated for 5 min with diaminobenzidine (Research Genetics, Huntsville, AL, USA). The sections were washed three times with distilled water, counterstained with Mayer's hematoxylin (Biogenex Laboratories, San Ramon, CA, USA), and washed once each with distilled water and PBS. Next, the slides were mounted using a Universal mount (Research Genetics) and examined under a bright-field microscope. A positive reaction was indicated by a reddishbrown precipitate in the cytoplasm (28, 29).
Statistics
The significance of the in vitro data was determined using Student's t-test (two-tailed), while that of the in vivo data was determined using the Kruskal-Willis U-test. A P-value of o0.05 was deemed significant.
